MetLife Investment Management’s PMV Pharmaceuticals PMVP Stock Holding History

MetLife Investment Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,144	Closed	-$136K	–	2854
2023 Q3	$136K	Hold	22,144	–	–	﹤0.01%	2419
2023 Q2	$139K	Hold	22,144	–	–	﹤0.01%	2494
2023 Q1	$106K	Hold	22,144	–	–	﹤0.01%	2526
2022 Q4	$193K	Hold	22,144	–	–	﹤0.01%	2266
2022 Q3	$264K	Buy	22,144 +2,636	+14%	+$38.1K	﹤0.01%	2112
2022 Q2	$278K	Buy	19,508 +2,690	+16%	+$39.1K	﹤0.01%	2070
2022 Q1	$350K	Buy	16,818 +6,207	+58%	+$109K	﹤0.01%	2001
2021 Q4	$245K	Hold	10,611	–	–	﹤0.01%	1932
2021 Q3	$316K	Hold	10,611	–	–	﹤0.01%	1793
2021 Q2	$362K	Sell	10,611 -11,013	-51%	-$368K	﹤0.01%	1770
2021 Q1	$711K	Buy	21,624 +15,385	+247%	+$606K	0.01%	1319
2020 Q4	$384K	Buy	+6,239	New	+$245K	﹤0.01%	1609

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MetLife Investment Management's PMVP Position: Q4 2023 in Review

MetLife Investment Management sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 22,144 shares — an estimated $136K sold.

MetLife Investment Management first reported a position in PMVP in Q4 2020 and held it in 12 quarters. The position peaked at $711K in Q1 2021. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

MetLife Investment Management reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
MetLife Investment Management sold 22,144 PMV Pharmaceuticals shares in Q4 2023, an estimated $136K.
MetLife Investment Management first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 12 quarters.
MetLife Investment Management's PMV Pharmaceuticals position peaked at $711K in Q1 2021.
98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.